17
Mar
2025
Why Cell & Gene Therapy Companies Should Talk with RFK Jr.
As the CEO of the cell and gene therapy advocacy organization the Alliance for Regenerative Medicine (ARM), I’ve been asked one question more than any other amid the constant barrage of news headlines the past two months. How are you approaching the Trump Administration? I hear it from across our community, including biotechnology companies, academic and medical research institutions, patient... Read More
17
Mar
2025
CAR-T cell Therapies Made In the Body: Andy Scharenberg on The Long Run
Andy Scharenberg is today’s guest on The Long Run. Andy is the co-founder and CEO of Seattle-based Umoja Biopharma. The company is developing in vivo CAR-T cell therapies. The idea is to use gene therapy, delivered in a single shot, that can reprogram T cells of the immune system to recognize markers on cancer cells and then hunt down cancer... Read More
17
Mar
2025
Curevo Captures $110M to Develop a More Tolerable Shingles Vaccine
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.